BiotechTube

Olipudase alfa

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acid Sphingomyelinase Deficiency (ASMD)

Conditions

Acid Sphingomyelinase Deficiency (ASMD)

Trial Timeline

Jun 10, 2022 → Dec 31, 2024

NCT ID
NCT05359276

About Olipudase alfa

Olipudase alfa is a pre-clinical stage product being developed by Sanofi for Acid Sphingomyelinase Deficiency (ASMD). The current trial status is completed. This product is registered under clinical trial identifier NCT05359276. Target conditions include Acid Sphingomyelinase Deficiency (ASMD).

What happened to similar drugs?

4 of 12 similar drugs in Acid Sphingomyelinase Deficiency (ASMD) were approved

Approved (4) Terminated (3) Active (6)
✅PantoprazolePfizerApproved
✅insulin glargine+ glulisine + NPH + Regular insulinSanofiApproved
✅Clinolipid + IntralipidBaxterApproved
✅Clinolipid + IntralipidBaxterApproved
🔄Omeprazole/sodium bicarbonate + omeprazole magnesium + sodium bicarbonateBayerPhase 3
🔄Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent)BayerPhase 3
🔄Zegerid + Prilosec OTC™ TabletsBayerPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT06192576Pre-clinicalRecruiting
NCT05359276Pre-clinicalCompleted
NCT06949358Phase 2Completed
NCT02292654Phase 1/2Completed

Competing Products

20 competing products in Acid Sphingomyelinase Deficiency (ASMD)

See all competitors
ProductCompanyStageHype Score
mRNA-3705ModernaPhase 2
0
"The MaP Study": Mapping the Patient Journey in MMA and PAModernaPreclinical
0
mRNA-3704ModernaPhase 2
0
A Retrospective Study to Characterize Participants With Propionic AcidemiaModernaPreclinical
0
mRNA-3705ModernaPhase 2
0
mRNA-3927ModernaPhase 2
0
mRNA-3927ModernaPhase 2
0
Low Dose REN001 + High Dose REN001OnKure TherapeuticsPhase 1
19
ONO-8539Ono PharmaceuticalPhase 1
29
LJN452 + Placebo to LJN452NovartisPhase 2
35
Insulin (Aspart Insulin [Novolog], Regular Insulin)Novo NordiskPre-clinical
26
PantoprazolePfizerApproved
43
Recombinant human acid sphingomyelinaseSanofiPhase 1
29
insulin glargine+ glulisine + NPH + Regular insulinSanofiApproved
43
AtalurenSanofiPhase 2
27
rhASM + rhASM + rhASM + rhASM + rhASMSanofiPhase 1
21
Omeprazole/sodium bicarbonate + omeprazole magnesium + sodium bicarbonateBayerPhase 3
37
Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent)BayerPhase 3
37
Zegerid + Prilosec OTC™ TabletsBayerPhase 3
37
A3384IpsenPhase 2
32